SAGE Labs Inc. Launches SAGEport™ Drug Transporter Assay Service

ST. LOUIS, Oct. 23, 2013 /PRNewswire/ -- SAGE Labs Inc., a leading provider of in vivo products, services and technologies in the field of genome engineering, today launched its SAGEport Drug Transporter Assay service.   The service will be used by researchers to evaluate the interactions of candidate drugs with various drug transporters in the context of a living system.

At the core of the SAGEport technology are rats that have been genetically engineered and validated to lack efflux and uptake drug transporters such as Mdr1a (Pgp), Bcrp, Mrp2, Oct1, Oct2, and Bsep. Recent publications by several pharmaceutical companies have demonstrated that transporter studies done with these knockout rat lines out-perform conventional studies done with chemical inhibitors.

Through the systematic dosing approach and analytic read out that is included in the service, candidate drugs can be quickly accessed as substrates for these common drug transporters. Data gleaned from SAGEport assays will be used to predict compound absorption properties that lead to efficacy and safety, critical factors in the development of life-saving drugs.

David Smoller, PhD., CEO of SAGE Labs, explained, "Recent guidance from the FDA has made it clear that there is a need for improved assays to test drugs for their interaction with efflux and uptake transporters. Our SAGEport assay service looks at these interactions in the context of a living biological system; providing a true surrogate to what is happening in a human being.

For more information on the SAGEport Drug Transporter Evaluation assay, please visit: http://www.sageresearchlabs.com/transporter-assays

About Sage Labs
SAGE® Labs is a world-class provider of next-generation research models and transgenic support services. Using proprietary platform technologies, such as Zinc Finger Nucleases (ZFN) and the CRISPR/cas9 system for genome engineering, SAGE produces complex in vivo research models in half the time as models produced using conventional technologies. For more information, visit http://www.sageresearchlabs.com.

About InterVivo Solutions
InterVivo Solution's mission is to develop and provide translational animal models and transformative research services in an effort to improve the clinical success of new drugs.  In addition to drug metabolism and pharmacokinetics screening and IND-enabling services, the company provides rodent models of cognitive function, obesity and addiction, pain and epilepsy, and Parkinson's disease. 

Media Contact:
Phil Simmons
(314) 313-7847
[email protected]

SOURCE SAGE Labs, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED